SCHEDULE 13G/A: Venrock Entities Reaffirm Passive 10.1% Stake in KalVista Pharmaceuticals

A group of Venrock Healthcare Capital Partners entities and individuals have reaffirmed their passive beneficial ownership of 10.1% of KalVista Pharmaceuticals, Inc.'s common stock.

Summary

• The filing is an Amendment No. 3 to a Schedule 13G, disclosing the beneficial ownership of common stock in KalVista Pharmaceuticals, Inc. by a group of Venrock Healthcare Capital Partners entities and individuals.
• The reporting group, consisting of Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, collectively beneficially owns 5,012,796 shares of KalVista Pharmaceuticals, Inc. common stock.
• This aggregate amount represents 10.1% of the Issuer's common stock outstanding, based on 49,417,986 shares outstanding as of December 4, 2024, as reported in KalVista's Form 10-Q.
• The beneficial ownership includes common stock and pre-funded warrants, with a 'Beneficial Ownership Blocker' provision preventing the exercise of warrants if it would result in ownership exceeding 9.99% of the outstanding common stock.
• The reporting persons have shared voting power and shared dispositive power over all 5,012,796 shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of KalVista Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: The filing is a routine regulatory disclosure of beneficial ownership and does not contain operational or financial performance updates, thus maintaining a neutral sentiment.

Positives

• Continued significant beneficial ownership by a group of Venrock Healthcare Capital Partners entities, indicating sustained investment interest from a specialized healthcare investor.
• The reporting persons have certified that their securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, suggesting stability in corporate governance and a passive investment approach.

Negatives

• None explicitly stated in the document, as this is a routine ownership disclosure.

Risks

• None explicitly stated in the document regarding KalVista Pharmaceuticals' operations or financial health.

Future Outlook

The document is a regulatory ownership disclosure and does not contain any forward-looking statements or guidance regarding KalVista Pharmaceuticals, Inc.'s future performance or strategic outlook.

Management Comments

• The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of KalVista Pharmaceuticals, Inc.

Industry Context

This filing is a standard disclosure of a significant passive ownership stake by a venture capital firm specializing in healthcare, common in the biotechnology and pharmaceutical sectors where institutional investors often hold substantial positions.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive institutional investor's stake, potentially offering reassurance regarding long-term investment interest and stability in corporate control.

Key Dates

Keywords

KalVista Pharmaceuticals, Venrock Healthcare Capital Partners, Schedule 13G/A, beneficial ownership, common stock, institutional investment, passive investment, biotechnology, pharmaceuticals